Postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma: a retrospective analysis of 426 cases
详细信息 查看全文
- 作者：Hailu Chen (1)
Zhiyong Wu (1)
Jiexin Chen (1)
Xiaorong Lin (1)
Chunpeng Zheng (1)
Yanghang Fan (1)
Zechun Zhang (1)
Xiaodong Yao (1)
Jianyi Wu (2)
Liyan Xu (2)
Enmin Li (2) - 关键词：Esophageal cancer ; Operation ; Adjuvant therapy ; Survival analysis
- 刊名：Medical Oncology
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：32
- 期：1
- 全文大小：629 KB
- 参考文献：1. Kumagai K, Rouvelas I, Tsai JA, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg. 2014;101:321-8. CrossRef
2. Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91-. CrossRef
3. Worni M, Martin J, Gloor B, et al. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg. 2012;215:643-1. CrossRef
4. Kurashige J, Kamohara H, Watanabe M, et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol. 2012;106:188-2. CrossRef
5. Chen H, Wang Z, Yang Z, et al. Prospective study of adjuvant radiotherapy on preventing lymph node metastasis after Ivor-lewis esophagectomy in esophageal cancer. Ann Surg Oncol. 2013;20:2721-. CrossRef
6. Lv J, Cao XF, Zhu B, et al. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol. 2010;16:1649-4. CrossRef
7. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68-4. CrossRef
8. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol. 2003;21:4592-. CrossRef
9. Lee J, Lee KE, Im YH, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2005;80:1170-. CrossRef
10. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-0. CrossRef
11. Huang WZ, Fu JHHuY, et al. Meta-analysis of postoperative adjuvant chemotherapy for localized esophageal carcinoma. Ai Zheng. 2006;25:1303-.
12. Zhang J, Zhang YW, Chen ZW, et al. Adjuvant chemotherapy of cisplatin, 5-fluorouracil and leucovorin for complete resectable esophageal cancer: a case-matched cohort study in east China. Dis Esophagus. 2008;21:207-3. CrossRef
13. Xu Y, Liu J, Du X, et al. Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer. Radiat Oncol. 2013;8:116. CrossRef
14. Lyu X, Huang J, Mao Y, et al. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? J Surg Oncol. 2014;110:864-. CrossRef
15. Zhang SS, Yang H, Xie X, et al. Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies. Dis Esophagus. 2014;27:574-4. CrossRef
16. Gao ZR, He J. Esophageal cancer. Beijing: Peking University Medical - 作者单位：Hailu Chen (1)
Zhiyong Wu (1)
Jiexin Chen (1)
Xiaorong Lin (1)
Chunpeng Zheng (1)
Yanghang Fan (1)
Zechun Zhang (1)
Xiaodong Yao (1)
Jianyi Wu (2)
Liyan Xu (2)
Enmin Li (2)
1. Department of Tumor Surgery, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou, 515041, China
2. The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, China - ISSN：1559-131X
文摘
The aim of this study was to evaluate the value of postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma (ESCC) in China. We retrospectively analyzed 426 eligible patients seen between October 2007 and November 2011. Specifically, we assessed clinicopathological characteristics and the disease-free and overall survival rates. Of the 426 patients, 272 cases underwent surgery alone, and 154 cases received postoperative adjuvant therapy (67 cases with radiotherapy, 57 cases with chemotherapy, and 30 cases with simultaneous chemoradiotherapy). The median follow-up time was 48.0?months (23.0-2.0?months), and the median survival time was 48.4?months (1.0-2.0?months). We found a significant difference between the surgery-alone and adjuvant therapy groups in the status of lymph node (LN) metastasis (N stage; P?P?P?>?0.05). A stratification analysis based on N stage suggested that the 5-year DFS and OS rates were similar in N0–N3 subgroups (P?>?0.05), except that patients with surgery alone had a higher 5-year DFS than those with postoperative adjuvant therapy in N0 subgroup (P?=?0.013). Our data suggest that patients with resectable thoracic ESCC may not benefit from postoperative adjuvant therapy. Further prospective studies are required to elucidate the utility of postoperative adjuvant therapy and to standardize individualized treatments for resectable ESCC.